Please use this identifier to cite or link to this item: https://ir.swu.ac.th/jspui/handle/123456789/14208
Title: Antimetastatic potential of N-acetylcysteine on human prostate cancer cells
Authors: Supabphol A.
Supabphol R.
Keywords: acetylcysteine
article
cancer inhibition
cell adhesion
cell invasion
cell migration
cell proliferation
cell survival
controlled study
cytotoxicity
enzyme linked immunosorbent assay
human
human cell
IC 50
metastasis
prostate cancer
Acetylcysteine
Adenocarcinoma
Cell Adhesion
Cell Line, Tumor
Cell Movement
Cell Proliferation
Dose-Response Relationship, Drug
Free Radical Scavengers
Humans
Male
Neoplasm Invasiveness
Prostatic Neoplasms
Issue Date: 2012
Abstract: Objective: N-acetylcysteine (NAC), is one of the cheapest, safest and widely used over-the-counter-drugs in Thailand. Here the authors examine the antimetastatic potential of NAC on the metastasis of human prostate cancer cells. Material and Method: Cytotoxicity of NAC to human prostate cancer cells, DU145 and PC3, were determined by proliferation assay using the 3-(4, 5-dimethylthiazol, 2-yl)-2,5-diphenyltetrazolium bromide (MTT) reagent. Cell migration and invasion were assessed by using a chemotaxis chamber containing membrane pre-coated with collagen IV and Matrigel®, respectively. Cell attachment onto the surface of the membrane coated with collagen IV was tested for its adhesion potentiality. Results: NAC could inhibit the growth of DU145 and PC3 cells. Suppression of migration and invasion of both human prostrate cancer cells were observed. Cell attachment to the collagen IV-coated surface was obviously reduced. All inhibitions occurred in a dose-dependent fashion in both cell lines. Conclusion: NAC could have a high potential in attenuating the migration of the human prostate cancer cells from their primary site and their adhesion and invasion to the remote locations. Hence, NAC might suppress the growth of the primary and the secondary tumors. Our findings suggest that NAC had a high possibility to become an antimetastatic agent for testing in clinical trials. Then, NAC might be used clinically as an optional adjuvant therapeutic drug in addition to the conventional standard treatment of human prostate cancer, obtaining a better outcome with the least toxic and affordable substance.
URI: https://ir.swu.ac.th/jspui/handle/123456789/14208
https://www.scopus.com/inward/record.uri?eid=2-s2.0-84876916324&partnerID=40&md5=42fc4951d6f4575719c408abe44cf859
ISSN: 1252208
Appears in Collections:Scopus 1983-2021

Files in This Item:
There are no files associated with this item.


Items in SWU repository are protected by copyright, with all rights reserved, unless otherwise indicated.